Feasibility study of electronic pen to help early diagnosis of dementia

ISRCTN ISRCTN11610863
DOI https://doi.org/10.1186/ISRCTN11610863
IRAS number 303834
Secondary identifying numbers CPMS 52890, IRAS 303834
Submission date
07/09/2023
Registration date
16/10/2023
Last edited
16/10/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
There are currently over 800,000 people with dementia in the U.K. Improving ability to diagnose dementia in its earlier stages and accurately can help ensure patients access appropriate treatment and support.
Researchers at a number of universities across Europe (including Newcastle University) have developed a pen system which assesses changes in movement and ability to write and draw. We are looking to study whether the pen system may help identify dementia and different types of dementia

Who can participate?
Those referred to North Tyneside memory clinic and local age matched individuals as controls.

What does the study involve?
Completing a series of basic drawing tests using the electronic pen on a touch sensitive tablet.

What are the possible benefits and risks of participating?
The pen is similar to a normal writing pen but it contains some sensors which detect movement. Previous studies of the pen conducted in the U.K., Netherlands and Ireland have not reported any adverse events.
There will be no direct benefit to participants. However, the study will allow us to assess whether the pen system could be used in a memory clinic setting and help identify dementia. If the study is successful then there may be potential for the pen to improve diagnosis of dementia and different types of dementia

Where is the study run from?
North Tyneside General Hospital (UK)

When is the study starting and how long is it expected to run for?
October 2022 to June 2024

Who is funding the study?
1. Innovate UK
2. Manus Neurodynamica Ltd (UK)

Who is the main contact?
Dr Christopher Davison, Christopher.davison@nhct.nhs.uk

Contact information

Dr Christopher Davison
Scientific

Northumbria Healthcare NHS Foundation Trust
North Tyneside General Hospital
Rake Lane
North Shields
NE29 8NH
United Kingdom

ORCiD logoORCID ID 0000-0001-6509-7059
Email Christopher.davison@nhct.nhs.uk

Study information

Study designNon-randomized; Interventional; Design type: Screening, Process of Care, Device
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleEvaluation of Neuromotor Pen in early identification of dementia and differential of dementia subtypes: a feasibility study
Study hypothesisWe are testing a novel, user-friendly and inexpensive pen system to aid in the differential diagnosis of dementia. It is hypothesized that the pen system can be developed to differentiate between dementia, MCI and normal subjects as well as potentially differentiating dementia subtype
Ethics approval(s)

Approved 17/10/2022, South East Scotland REC2 (2ndFloor, Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG, United Kingdom; +44 131 5369000; ruth.fraser4@nhslothian.scot.nhs.uk), ref: 22/SS/0039

ConditionDementia
InterventionPatients and carers will be consented to perform a series of written/drawing tests using the NMP taking between 5 and 15 minutes. These will be incorporated into memory clinic assessment with patients consent. Rating of acceptability of testing will be tested with a basic questionnaire and rating scales. Results of tests will be compared to tests results from the memory clinic assessment so not to add significant extra time to assessments and to compare with normal practice.
Intervention typeDevice
Pharmaceutical study type(s)Not Applicable
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Neuromotor Pen
Primary outcome measureThe level of agreement between the pen system and clinical diagnosis. The assessment by a specialist clinician will be conducted as part of routine assessment of suspected dementia
Secondary outcome measuresThere are no secondary outcome measures
Overall study start date17/10/2022
Overall study end date01/06/2024

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 100; UK Sample Size: 100
Participant inclusion criteria1. Capacitated individuals attending memory clinic for assessment of possible dementia
2. Carers may be invited to act as controls
3. Willing and able to provide written informed consent
4. Aged 18 years or older
Participant exclusion criteria1. Lack of capacity
2. Significant visual impairment
3. Significant upper limb physical functional impairment
4. Under 18 years old
5. Unable to communicate in English
Recruitment start date19/12/2022
Recruitment end date31/12/2024

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

North Tyneside General Hospital
Rake lane
North Shields
NE29 8NH
United Kingdom

Sponsor information

Northumbria Healthcare NHS Foundation Trust
Hospital/treatment centre

North Tyneside General Hospital
Rake Lane
North Shields
NE29 8NH
England
United Kingdom

Phone +44 1912934087
Email peta.heslop@nhct.nhs.uk
Website https://www.northumbria.nhs.uk/
ROR logo "ROR" https://ror.org/01gfeyd95

Funders

Funder type

Government

Innovate UK
Government organisation / National government
Alternative name(s)
innovateuk
Location
United Kingdom
Manus Neurodynamica Ltd

No information available

Results and Publications

Intention to publish date31/12/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryPublished as a supplement to the results publication
Publication and dissemination planNot provided at time of registration
IPD sharing planAll data generated or analysed during this study will be included in the subsequent results publication

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol file version 1.3 11/07/2023 03/10/2023 No No

Additional files

44251 Protocol V1.3.pdf

Editorial Notes

07/09/2023: Study's existence confirmed by the NIHR.